From promise to people.

At Lineage, our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions

Our
Pipeline

Company
Presentation

Genentech and Lineage are working together to expand benefits of cell therapy to eye diseases

We’re teaming up to create allogeneic retinal pigment epithelial (RPE) cells to either replace or support cells that are dysfunctional or absent due to degenerative disease

In May 2024, we announced a new services agreement with Genentech

Additional clinical, technical, training and manufacturing services to further support the ongoing advancement and optimization of the OpRegen® program

In the Media

View more media

OPC1 Patient Spotlight

Sonia’s OpRegen Story

News and Events

View more news and events

November 14, 2024 – Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
May 6, 2024 – OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Recent Financials

Listen to our Q3 2024
Earnings Call